Mirae Asset Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare Index (TRI)) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Equity | 99.67% |
| Cash & Equivalents | 0.32% |
| Mutual Funds | 0.01% |
Click a sector to filter the holdings below (holdings map to our sector list where the company is known).
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.90% | -0.05 pp | 143.5 |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.90% | — | 143.5 |
| Divi's Laboratories Ltd | Healthcare | 9.91% | 2.38 pp | 83.0 |
| Divi's Laboratories Ltd. | Healthcare | 9.91% | — | 83.0 |
| Torrent Pharmaceuticals Ltd | Healthcare | 7.06% | 6.60 pp | 77.7 |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.06% | — | 77.7 |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.91% | -0.18 pp | 73.1 |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.91% | — | 73.1 |
| Laurus Labs Ltd | Healthcare | 5.24% | 0.63 pp | 122.0 |
| Laurus Labs Ltd. | Healthcare | 5.24% | — | 122.0 |
| Glenmark Pharmaceuticals Limited | Healthcare | 4.99% | -1.10 pp | 316.1 |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 4.99% | — | 316.1 |
| Dr. Reddy's Laboratories Limited | Healthcare | 3.94% | -0.39 pp | 150.9 |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 3.94% | — | 150.9 |
| Aurobindo Pharma Limited | Healthcare | 3.81% | -0.52 pp | 37.5 |
| Aurobindo Pharma Ltd. | Healthcare | 3.81% | — | 37.5 |
| IPCA Laboratories Ltd | Healthcare | 3.43% | 0.20 pp | 39.8 |
| IPCA Laboratories Ltd. | Healthcare | 3.43% | — | 39.8 |
| Fortis Healthcare Ltd | Healthcare | 3.40% | -0.40 pp | 255.5 |
| Fortis Healthcare Ltd. | Healthcare | 3.40% | — | 255.5 |
| Alkem Laboratories Ltd. | Healthcare | 3.39% | — | 29.1 |
| Alkem Laboratories Ltd | Healthcare | 3.39% | -0.16 pp | 29.1 |
| Sai Life Sciences Limited | Healthcare | 3.30% | 0.04 pp | 89.9 |
| Sai Life Sciences Ltd. | Healthcare | 3.30% | — | 89.9 |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 3.16% | -0.69 pp | 105.1 |
| Krishna Institute of Medical Sciences Ltd. | Healthcare | 3.16% | — | 105.1 |
| Aster DM Quality Care Limited | Healthcare | 3.01% | -0.16 pp | 205.8 |
| Aster DM Quality Care Ltd. | Healthcare | 3.01% | — | 205.8 |
| Onesource Specialty Pharma Ltd | Healthcare | 2.96% | -0.39 pp | 358.6 |
| Onesource Specialty Pharma Ltd. | Healthcare | 2.96% | — | 358.6 |
| Dr. Lal Path labs Ltd. | Healthcare | 2.77% | — | 38.4 |
| Dr. Lal PathLabs Ltd | Healthcare | 2.77% | 0.19 pp | 38.4 |
| Cipla Ltd | Healthcare | 2.71% | -0.48 pp | 35.1 |
| Cipla Ltd. | Healthcare | 2.71% | — | 35.1 |
| Max Healthcare Institute Limited | Healthcare | 2.58% | -0.48 pp | 124.3 |
| Max Healthcare Institute Ltd. | Healthcare | 2.58% | — | 124.3 |
| Eris Lifesciences Ltd | Healthcare | 2.55% | -0.61 pp | 84.5 |
| Eris Lifesciences Ltd. | Healthcare | 2.55% | — | 84.5 |
| Gland Pharma Ltd | Healthcare | 2.44% | -0.06 pp | 34.4 |
| Gland Pharma Ltd. | Healthcare | 2.44% | — | 34.4 |
| Lupin Limited | Healthcare | 2.40% | -1.73 pp | 13.2 |
| Lupin Ltd. | Healthcare | 2.40% | — | 13.2 |
| Biocon Limited | Healthcare | 2.13% | 1.61 pp | 596.5 |
| Biocon Ltd. | Healthcare | 2.13% | — | 596.5 |
| Mankind Pharma Ltd | Healthcare | 2.13% | 0.02 pp | 46.9 |
| Mankind Pharma Ltd. | Healthcare | 2.13% | — | 46.9 |
| Molbio Diagnostics Limited | Healthcare | 1.44% | 1.44 pp | — |
| Molbio Diagnostics Ltd. | Healthcare | 1.44% | — | — |
| Anthem Biosciences Limited | Healthcare | 1.13% | -0.03 pp | 76.6 |
| Anthem Biosciences Ltd. | Healthcare | 1.13% | — | 76.6 |
| Symbiotec Pharmalab Limited | Healthcare | 0.98% | 0.98 pp | — |
| Symbiotec Pharmalab Ltd A** | Healthcare | 0.98% | — | — |
| Narayana Hrudayalaya Limited | Healthcare | 0.91% | -0.31 pp | 61.9 |
| Narayana Hrudayalaya Ltd. | Healthcare | 0.91% | — | 61.9 |
| Neogen Chemicals Ltd | Chemicals | 0.64% | -0.00 pp | 118.2 |
| Neogen Chemicals Ltd. | Chemicals | 0.64% | — | 118.2 |
| Deepak Nitrite Ltd | Chemicals | 0.45% | 0.02 pp | 91.4 |
| Deepak Nitrite Ltd. | Chemicals | 0.45% | — | 91.4 |
| TREPS | — | 0.44% | 0.08 pp | — |
| TREPS | — | 0.44% | — | — |
| Mirae Asset Liquid Fund-Direct Plan-Growth | — | 0.01% | -0.00 pp | — |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 0.47% · Nov 25 0.47% · Dec 25 0.48% · Jan 26 0.48% · Feb 26 0.47% · Mar 26 0.51% · Apr 26 0.59% · May 26 0.52% · Jun 26 0.62% · Jul 26 0.61% · Aug 26 0.61% · Sep 26 0.61%
If redeemed within 1 month (30 days) from the date of allotment: 1% If redeemed after 1 month (30 days) from the date of allotment: NIL
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies/Entities benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns. There is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
